FDG-PET/CT评估的肿瘤代谢与基因组分级指数评估的肿瘤增殖预测三阴性乳腺癌新辅助化疗反应
研究纳入55例三阴性乳腺癌患者,于新辅助化疗前及2周期后行FDG-PET/CT,并在治疗前活检中检测基因组分级指数(GGI)等分子标志物。结果显示ΔSUVmax与病理完全缓解(pCR)高度相关(P=0.0001),GGI(P=0.04)及其组分KPNA2(P=0.04)有预测价值,基线SUVmax联合GGI使pCR预测AUC从0.63升至0.76(P=0.016)。
要点
- 新辅助化疗期间早期肿瘤代谢变化(ΔSUVmax)与pCR高度相关(P=0.0001)。
- 治疗前活检GGI(P=0.04)及其组分KPNA2(P=0.04)对pCR有预测价值。
- 基线SUVmax联合GGI使pCR预测AUC从0.63升至0.76(P=0.016)。
核心结论
- 新辅助化疗期间早期肿瘤代谢变化是预测三阴性乳腺癌患者pCR和结局的有力参数。
- 治疗前活检测定的GGI也可预测pCR,GGI联合基线SUVmax可改善预测。
研究设计与样本
- 研究在治疗前活检中检测分子参数,于新辅助化疗前和2周期后各行一次PET/CT测量肿瘤代谢活性,化疗后标本判定pCR,采用Kaplan-Meier法估计无事件生存期(EFS)。
- 共纳入55例三阴性乳腺癌患者。
主要发现
- 55例三阴性乳腺癌患者中19例(35%)在新辅助化疗后达到pCR。
- 肿瘤分级和Ki67与pCR无关,而GGI(P=0.04)及其组分KPNA2(P=0.04)显示预测价值。
- PET1与PET2之间FDG摄取变化(ΔSUVmax)与pCR高度相关(P=0.0001),而基线SUVmax绝对值与pCR无关(P=0.11)。
- 基线SUVmax联合GGI时pCR预测AUC从0.63升至0.76(P=0.016)。
- 与EFS相关的仅有两个参数:ΔSUVmax(P=0.048)和病理反应(P=0.014)。
关键数值与推荐
- pCR定义为新辅助化疗后标本判定。
- GGI预测pCR的P=0.04,其组分KPNA2预测pCR的P=0.04。
- ΔSUVmax预测pCR的P=0.0001,基线SUVmax绝对值预测pCR的P=0.11。
- 基线SUVmax联合GGI预测pCR的AUC从0.63升至0.76(P=0.016)。
- ΔSUVmax与EFS相关P=0.048,病理反应与EFS相关P=0.014。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Survival is increased when pathological complete response (pCR) is reached after neoadjuvant chemotherapy (NAC), especially in triple-negative breast cancer (TNBC) patients. Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) and the genomic grade index (GGI), each separately, showed good potential to predict pCR. Our study was designed to evaluate the predictive value for the therapeutic response of a combination of parameters based on FDG-PET, histoclinical features and molecular markers of proliferation. METHODS: Molecular parameters were measured on pre-treatment biopsy. Tumor metabolic activity was measured using two PET/CT scans, one before and one after 2 cycles of NAC. The pCR was determined on specimen after NAC. Event-free survival (EFS) was estimated using the Kaplan Meier method. RESULTS: Of 55 TNBC patients, 19 (35%) reached pCR after NAC. Tumor grade and Ki67 were not associated with pCR whereas GGI (P = 0.04) and its component KPNA2 (P = 0.04) showed a predictive value. The change of FDG uptake between PET1 and PET2 (ΔSUVmax) was highly associated with pCR (P = 0.0001) but the absolute value of baseline SUVmax was not (P = 0.11). However, the AUC of pCR prediction increased from 0.63 to 0.76 when baseline SUVmax was combined with the GGI (P = 0.016). The only two parameters associated with EFS were ΔSUVmax (P = 0.048) and pathological response (P = 0.014). CONCLUSIONS: The early tumor metabolic change during NAC is a powerful parameter to predict pCR and outcome in TNBC patients. The GGI, determined on pretreatment biopsy, is also predictive of pCR and the combination GGI and baseline SUVmax improves the prediction.
引用
- Groheux D, Biard L, Lehmann-Che J, et al. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. Eur J Nucl Med Mol Imaging. 2018. PMID: 29616304. doi:10.1007/s00259-018-3998-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。